Upregulation of the mTOR pathway has also been illustrated in significant proportions of NSCLC tumors, with increased p‐mTOR in up to 90% of patients with adenocarcinoma, 60% of patients with large cell carcinoma and 40% of patients with squamous cell carcinoma.51, 52, 53 Downstream products of mTOR activation, S6K and 4E‐BP1 have also been identified in up to 58% and 25% of NSCLC specimens respectively, with a greater predominance in adenocarcinoma.54 There is also a strong correlation of p‐S6K and p‐mTOR positivity. This evidence concerns the gene MTOR and non-small cell lung carcinoma.